Stockscreener 앱 받기
18.53
3.46%
0.62
시간 외 거래:
18.51
-0.02
-0.11%
전일 마감가:
$17.91
열려 있는:
$18.11
하루 거래량:
1.42M
Relative Volume:
1.17
시가총액:
$2.10B
수익:
$4.02M
순이익/손실:
$-224.59M
주가수익비율:
-7.7874
EPS:
-2.3795
순현금흐름:
$-205.52M
1주 성능:
+2.04%
1개월 성능:
-11.25%
6개월 성능:
-6.32%
1년 성능:
+107.04%
1일 변동 폭
$17.95
$18.63
1주일 범위
$17.83
$19.05
52주 변동 폭
$7.96
$27.65
이뮤놈 Stock (IMNM) Company Profile
명칭
Immunome Inc
전화
610-321-3700
주소
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
18.53 | 2.05B | 4.02M | -224.59M | -205.52M | -2.3795 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
이뮤놈 Stock (IMNM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-12 | 개시 | H.C. Wainwright | Buy |
| 2025-12-01 | 개시 | Truist | Buy |
| 2025-09-22 | 개시 | Goldman | Buy |
| 2025-09-05 | 개시 | Craig Hallum | Buy |
| 2025-04-02 | 개시 | Lake Street | Buy |
| 2024-11-08 | 개시 | Stephens | Overweight |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-04-30 | 개시 | JP Morgan | Overweight |
| 2024-04-15 | 개시 | Guggenheim | Buy |
| 2024-01-29 | 개시 | Leerink Partners | Outperform |
| 2023-12-19 | 개시 | Wedbush | Outperform |
| 2021-10-29 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
이뮤놈 주식(IMNM)의 최신 뉴스
(IMNM) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
How Immunome’s First-in-Human IM-1617 ADC Trial At Immunome (IMNM) Has Changed Its Investment Story - simplywall.st
IMNM (NASDAQ: IMNM) director plans to sell 60,000 shares via option - Stock Titan
Immunome (IMNM) director receives 9,897 stock options at $18.16 strike price - Stock Titan
[Form 4] Immunome Inc. Insider Trading Activity - Stock Titan
Immunome (IMNM) director granted stock options on 9,897 common shares - Stock Titan
Immunome (IMNM) director-linked entity awarded 9,897 stock options at $18.16 strike - Stock Titan
Immunome (IMNM) director Carol Schafer receives grant of 9,897 stock options - Stock Titan
Immunome (IMNM) 2026 meeting: directors elected, pay and auditor votes pass - Stock Titan
IMNM Reiterated by Wedbush -- Price Target Maintained at $31 - GuruFocus
Craig-Hallum Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $36 - Moomoo
LifeSci Capital Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Immunome (IMNM) Begins First Phase 1 Trial for IM-1617 - GuruFocus
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors - BioSpace
Immunome doses first patient in IM-1617 cancer therapy trial - Investing.com
Immunome director Bienaime sells $203k, buys $204k in same-day trades By Investing.com - Investing.com Australia
Immunome director Bienaime sells $203k, buys $204k in same-day trades - Investing.com Australia
IMNM SEC FilingsImmunome Inc 10-K, 10-Q, 8-K Forms - Stock Titan
IMNM: Varegacestat nears launch with strong data; ADC pipeline advances with key readouts ahead - TradingView
Immunome: Varegacestat Is The Beachhead, But The ADC Engine Is The Thesis (NASDAQ:IMNM) - Seeking Alpha
Can Varegacestat’s Broad Efficacy Profile Redefine Immunome’s (IMNM) Rare Oncology Investment Narrative? - simplywall.st
4 Biotech Stocks Investors Should Watch in 2026 - TradingView
Immunome earnings up next: Cash burn eyed after NDA filing By Investing.com - Investing.com UK
Immunome (IMNM) Is Down 12.7% After Phase 3 Varegacestat Data And FDA NDA FilingHas The Bull Case Changed? - Yahoo Finance
Immunome earnings up next: Cash burn eyed after NDA filing - Investing.com
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - standard-journal.com
A Look At Immunome (IMNM) Valuation After New Barclays Overweight Coverage - Sahm
Piper Sandler Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $33 - Moomoo
H.C. Wainwright Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Barclays Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Immunome (IMNM) Reveals Promising Results in Phase 3 Trial of Va - GuruFocus
Immunome (IMNM) Reveals Promising Results in Phase 3 Trial of Varegacestat - GuruFocus
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacesta - The National Law Review
Immunome’s Varegacestat Phase 3 RINGSIDE Trial Results Presented at ASCO 2026 Show Progression-Free Survival Data in Desmoid Tumors - geneonline.com
Immunome announced positive clinical trial results for its drug Varegacestat. - Bitget
Immunome presents phase 3 trial results for desmoid tumor drug By Investing.com - Investing.com South Africa
Immunome presents phase 3 trial results for desmoid tumor drug - Investing.com
Immunome Says Varegacestat Treatment Resulted In Statistically Significant Improvements In Primary And All Key Secondary Efficacy Endpoints - TradingView
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting - Business Wire
Does Barclays’ Bullish Stance Refocus Immunome’s (IMNM) Investment Narrative on Its ADC Platform? - simplywall.st
Immunome (IMNM) Receives a New Rating from Barclays - The Globe and Mail
IMNM Maintained by Truist Securities -- Price Target Raised to $37 - GuruFocus
Immunome Is Maintained at Buy by Truist Securities - Moomoo
Immunome Price Target Raised to $37.00/Share From $36.00 by Truist Securities - Moomoo
IMNM Initiates Coverage On Barclays -- Rating Set to Overweight - GuruFocus
Truist raises Immunome stock price target on desmoid tumor drug By Investing.com - Investing.com Australia
Truist Financial Initiates Immunome(IMNM.US) With Buy Rating, Announces Target Price $37 - Moomoo
Barclays initiates Immunome stock coverage with overweight rating - Investing.com UK
Truist raises Immunome stock price target on desmoid tumor drug - Investing.com
Barclays Initiates Immunome at Overweight With $36 Price Target - marketscreener.com
Barclays initiates Immunome stock coverage with overweight rating By Investing.com - Investing.com Australia
이뮤놈 (IMNM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
이뮤놈 주식 (IMNM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | Director |
Jun 05 '26 |
Buy |
19.45 |
10,500 |
204,260 |
43,415 |
| BIENAIME JEAN JACQUES | Director |
Jun 05 '26 |
Sale |
19.41 |
10,500 |
203,820 |
32,915 |
| BIENAIME JEAN JACQUES | Director |
May 15 '26 |
Buy |
20.70 |
5,000 |
103,500 |
43,415 |
| Higgins Jack | Chief Scientific Officer |
Apr 02 '26 |
Sale |
21.64 |
9,438 |
204,238 |
22,000 |
| Rosett Max | Chief Financial Officer |
Apr 02 '26 |
Option Exercise |
1.22 |
71,561 |
87,053 |
119,037 |
| Rosett Max | Chief Financial Officer |
Apr 02 '26 |
Sale |
21.92 |
65,000 |
1,424,916 |
54,037 |
2.60%
0.94%
자본화:
|
볼륨(24시간):